November 2, 2022Open Access

Once-Weekly Semaglutide in Adolescents with Obesity

Key Points

Key points are not available for this paper at this time.

Abstract

Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone. (Funded by Novo Nordisk; STEP TEENS ClinicalTrials.gov number, NCT04102189.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Weghuber et al. (Wed,) studied this question.

synapsesocial.com/papers/69d71e0bcd480cb7e5f5083c https://doi.org/https://doi.org/10.1056/nejmoa2208601

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity2020 · 377 citations
2Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s Pediatric Suicidal Risk Analysis of Antidepressants2007 · 738 citations
3Screening for Obesity and Intervention for Weight Management in Children and Adolescents2017 · 498 citations
4Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation2017 · 1,524 citations
5Assessing Weight‐Related Quality of Life in Adolescents2006 · 214 citations

Bookmark

View Full Paper